Ann: Bionomics and Merck Collaboration Presentation, page-10

Well Alzheimers is a massive market, and getting bigger. they are also not involved in a marketing agreement, but in a much bigger deal than that. I would hope that Bionomics have covered off expected timeframes and minimum investments at each stage etc to protect themselves. Priorities could change, but there are few products on the market that are successful in ameliorating Alzheimers. and the demographic of interest generally has money, and the costs of Alzheimers is massive, in terms of care, let alone forgone life experiences and expectancy.